(19)
(11) EP 4 531 851 A1

(12)

(43) Date of publication:
09.04.2025 Bulletin 2025/15

(21) Application number: 23735395.8

(22) Date of filing: 01.06.2023
(51) International Patent Classification (IPC): 
A61K 31/4439(2006.01)
A61P 25/24(2006.01)
A61K 45/06(2006.01)
A61K 9/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/4439; A61P 25/24; A61K 45/06; A61K 9/0019; A61K 9/19; A61K 9/08
 
C-Sets:
A61K 31/4439, A61K 2300/00;
(86) International application number:
PCT/IB2023/055651
(87) International publication number:
WO 2023/233357 (07.12.2023 Gazette 2023/49)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 02.06.2022 US 202263365749 P

(71) Applicant: Novartis AG
4056 Basel (CH)

(72) Inventors:
  • FALLER, Thomas Herbert
    4002 Basel (CH)
  • KOEHNE-VOSS, Stephan Josef
    4002 Basel (CH)
  • KORADIA, Vishal Shamji
    4002 Basel (CH)
  • PAPANICOLAOU, Dimitris Angelo
    East Hanover, New Jersey 07936 (US)
  • SERBAN, Carmen-Gabriela
    4002 Basel (CH)

(74) Representative: Potter Clarkson 
Chapel Quarter Mount Street
Nottingham NG1 6HQ
Nottingham NG1 6HQ (GB)

   


(54) SUBCUTANEOUS ADMINISTRATION OF ONFASPRODIL AND DOSING METHODS FOR USE IN THE TREATMENT OF DEPRESSION DISORDERS